Less Survivable Cancers

Helen Maguire Excerpts

Tuesday 6th January 2026 Westminster Hall

[Helen Maguire (Epsom and Ewell) (LD)]

It is a pleasure to serve under your chairship, Mr Efford. I thank my hon. Friend the Member for Wokingham (Clive Jones) both for securing this debate and for his tireless advocacy on this subject.

In Epsom and Ewell, there are around 650 new cancer cases every year and around 240 cancer deaths, and the local integrated care board missed the 62-day treatment target as recently as October 2025. The Lib Dems have called for a guarantee that 100% of patients can start treatment within 62 days of urgent referral.

It is easy to get lost in the numbers—those who have been diagnosed with cancer, those who have not survived, the waiting times for treatment and the performance of hospitals—but behind each number is a person with a story that must be told. A constituent wrote to me about her husband, who battled pancreatic cancer. Only one in four people diagnosed with pancreatic cancer survives beyond a year. As happens in so many cases, her husband’s cancer was not diagnosed until it had become terminal. He died within six weeks of diagnosis.

A recent story shared with me by the British Liver Trust about Jane’s husband also powerfully highlights the importance of early diagnosis of liver cancer. He was known to be at high risk because of an underlying liver condition and was meant to receive regular surveillance scans. These scans were meant to detect cancer early, when treatment options are greater and outcomes can be better. However, delays and disruption to his regular surveillance scans meant that his cancer was not diagnosed until it was already advanced.

Jane believes that had her husband’s monitoring continued as planned, his cancer could have been diagnosed at an earlier stage, when potentially lifesaving treatment and interventions were still possible. Her husband’s experience is a clear reminder of the importance of regular surveillance of people who are at risk, so that liver cancer can be detected at the earliest possible stage, when lives can still be saved.

Such stories paint a stark picture of the shockingly poor outcomes for individuals diagnosed with less survivable cancers. The UK has the highest rate of oesophageal cancer in the world, and only 15% of adult patients with oesophageal cancer survive for five years or more. A mere 15% of stomach cancer patients in the UK will survive for more than 10 years. Liver cancer survival rates have hardly changed in the last decade. And despite the work to tackle smoking, lung cancer still claims the lives of around 91 people every day.

Today, on average, the chance of someone surviving for five years after being diagnosed with one of the six least survivable cancers is only 16%. For the country that discovered penicillin, designed the world’s first insulin infusion device and uncovered the structure of DNA, we are dangerously behind. OECD research shows that the UK ranks a dismal 31st out of 43 countries for how many people survive at least five years after being diagnosed with lung cancer. Across lung cancer survival rates, the UK is below the EU and OECD averages, as well as below the US, Germany and France. For all the less survivable cancers, survival rates have increased by only a small amount over the last 50 years, and all remain below 20%.

In my role as Liberal Democrat primary care and cancer spokesperson, I have spent time meeting charities to try to understand why the outcomes for patients with the six least survivable cancers are not improving. One resounding reason is research. A response to a question tabled by my hon. Friend the Member for Witney (Charlie Maynard) revealed that the Department of Health and Social Care’s funding for research into each of the less survivable cancers since 2022 is as follows: for lung cancer, £16 million; for oesophageal cancer, £9.4 million; bladder and stomach cancer, £3 million each; liver cancer, £2 million; pancreatic cancer, £0.9 million; and brain cancer, £0.6 million. That funding is pitifully low, considering that UK survival rates for many of those cancers are devastatingly behind our international counterparts. What adds to that frustration is that even after a successful innovation is found, thanks to the tireless work of researchers, implementation is simply far too slow.

The less survivable cancers taskforce told me that senior surgeons are reporting the start of a golden time for approaches to cancer, but that the UK takes too long to implement any innovations and the later stages of clinical trials drag on for too long. For example, a diagnostic test—the capsule sponge—that allows cell changes associated with oesophageal cancer to be identified has spent 20 years in the research phase. Only last year did the test enter its next trial in certain parts of the country. Although that is welcome, progress overall is far too slow.

International Cancer Benchmarking Partnership data shows that in the 1990s Denmark and the UK were two of the worst performers for cancer care. While the UK has made some progress, Denmark has surged ahead. In fact, since 1995, Denmark has seen some of the biggest improvements of any ICBP member, with survival across all seven ICBP-measured cancer types increasing by more than it has in the UK. A key factor has been Denmark’s focus on using consistent cancer plans to co-ordinate investment, drive reform and develop strong clinical leadership.

That is why the Liberal Democrats are calling for a cancer survival research Act to require the Government to co-ordinate and ensure funding for research into cancers with the lowest survival rates. Alongside that, expanding the capacity of the Medicines and Healthcare products Regulatory Agency would halve the time it takes for new treatments to reach patients.

Before Christmas, I visited the Shooting Star hospice in Guildford and stood in the room where families can grieve next to their children. Many of those children receive palliative care for cancer. Every death is a tragedy, but that visit was a harrowing reminder of how quickly and devastatingly cancer takes even the youngest lives. As we enter the new year, I ask that the Minister makes it her resolution to tackle the black hole of research funding for less survivable cancers and to speed up the snail’s-pace implementation of lifesaving treatments.